ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG evidence brief
What we can confirm
- Market Cap:
- $1.53B
What it means
What to watch
Prepared research question
What matters most for AAPG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL is a China-based commercial-stage biopharmaceutical company focused on developing and commercializing therapies for hematological malignancies, with two approved products in China (Olverembatinib and Lisaftoclax) and a pipeline of earlier-stage candidates.
Key risk: No ex-China approvals
Market Cap
$1.53B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 12 clinical trials for ASCENTAGE PHARMA GROUP INTERNATIONAL.
ASCENTAGE PHARMA GROUP INTERNATIONAL is a China-based commercial-stage biopharmaceutical company focused on developing and commercializing therapies for hematological malignancies, with two approved products in China (Olverembatinib and Lisaftoclax) and a pipeline of earlier-stage candidates.
- As of December 31, 2025, the company had RMB2,470.1 million (US$353.2 million) in cash and bank balances [sec · filed 2026-04-29].
- As of December 31, 2025, accumulated losses were RMB7,013.3 million (US$1,002.9 million) [sec · filed 2026-04-29].
- The company has obtained regulatory approval in China for Olverembatinib (for chronic myeloid leukemia) and Lisaftoclax, but has not received approval for either drug outside of China [sec · filed 2026-04-29].
- The company expects to continue incurring operating losses for the foreseeable future and will need additional financing to complete development and commercialization of its drug candidates [sec · filed 2026-04-29].
What works
- The company has two approved products (Olverembatinib and Lisaftoclax) in China, providing a commercial-stage revenue base [sec · filed 2026-04-29].
- As of December 31, 2025, the company held substantial cash resources of RMB2,470.1 million (US$353.2 million) to fund ongoing operations [sec · filed 2026-04-29].
What to weigh
- The company has not obtained regulatory approval for Olverembatinib or Lisaftoclax outside of China, limiting its market to one jurisdiction [sec · filed 2026-04-29].
- As of December 31, 2025, accumulated losses totaled RMB7,013.3 million (US$1,002.9 million), and the company expects to continue incurring operating losses for the foreseeable future [sec · filed 2026-04-29].
- The company will need additional financing to complete development and commercialization of its drug candidates, and failure to obtain such financing could materially impair its business [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2025
“As of December 31, 2025 we had RMB2,470.1 million ( US$353.2 million) in cash and bank”
SEC filings · April 29, 2026
Accumulated losses as of December 31, 2025
“As of December 31, 2025, we had accumulated losses of RMB7,013.3 million (US$1,002.9 million).”
SEC filings · April 29, 2026
Regulatory approvals limited to China
“we have obtained regulatory approval in China for (a) Olverembatinib for the treatment of adult patients with chronic myeloid leukemia in chronic phase, or CML-CP, or”
SEC filings · April 29, 2026
Need for additional financing
“We will need to obtain additional financing to fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our drug candidates, including Olverembatinib and Lisaftoclax.”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- No ex-China approvals — Olverembatinib and Lisaftoclax are approved only in China; no marketing authorization outside China has been obtained [sec · filed 2026-04-29].
- Accumulated losses and cash burn — Accumulated losses of RMB7,013.3M as of Dec 2025; company expects continued operating losses and needs additional financing [sec · filed 2026-04-29].
- Clinical trial uncertainty — Many drug candidates are in early stages; failure or delay in development would materially adversely affect business [sec · filed 2026-04-29].
- Dependence on two products — Business depends substantially on success of Olverembatinib and Lisaftoclax; no other approved products in any market [sec · filed 2026-04-29].
What to watch
- Progress of regulatory submissions for Olverembatinib and Lisaftoclax outside of China [sec · filed 2026-04-29].
- Ability to secure additional financing to fund ongoing operations and clinical development [sec · filed 2026-04-29].
- Clinical trial outcomes for pipeline candidates beyond the two approved drugs [sec · filed 2026-04-29].
Sources: SEC filings · Generated September 30, 2026 · How we verify sources →
Run ASCENTAGE PHARMA GROUP INTERNATIONAL through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ASCENTAGE PHARMA GROUP INTERNATIONAL facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$722K
| Holder | Shares | Value |
|---|---|---|
| point72 asset management, l.p. | 16,056 | $383K |
| xy capital ltd | 13,014 | $311K |
| tower research capital llc (trc) | 518 | $12K |
| morgan stanley | 498 | $12K |
| ubs group ag | 124 | $3K |
| eversource wealth advisors, llc | 24 | $573 |
| royal bank of canada | 6 | $0 |
Short Interest
as of May 19, 2026- % of float
- 0.0%
- Days to cover
- 0.0
- Shares short
- 16
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AAPG short interestFrequently asked questions
What is the AI investment thesis for ASCENTAGE PHARMA GROUP INTERNATIONAL?
ASCENTAGE PHARMA GROUP INTERNATIONAL is a China-based commercial-stage biopharmaceutical company focused on developing and commercializing therapies for hematological malignancies, with two approved products in China (Olverembatinib and Lisaftoclax) and a pipeline of earlier-stage candidates.
Who is the CEO of ASCENTAGE PHARMA GROUP INTERNATIONAL?
Dr. Dajun Yang M.D., Ph.D. is the chief executive officer of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG).
Where is ASCENTAGE PHARMA GROUP INTERNATIONAL headquartered?
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) is headquartered in Suzhou, China.
What therapeutic areas does ASCENTAGE PHARMA GROUP INTERNATIONAL focus on?
ASCENTAGE PHARMA GROUP INTERNATIONAL develops therapies across Oncology, Immunology, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.